(MedPage Today) — CHICAGO — Treatment of giant cell arteritis (GCA) with the oral drug upadacitinib (Rinvoq) was durably effective when continued for 2 years, results from a phase III trial extension indicated.
Some 85% of patients remained…
Source link : https://www.medpagetoday.com/meetingcoverage/acr/118147
Author :
Publish date : 2025-10-26 21:12:00
Copyright for syndicated content belongs to the linked Source.
